Read the full article here.
Tucson, AZ, — A recent survey by GenomeWeb has illuminated the growing enthusiasm within the research and clinical communities for Multi-Cancer Early Detection (MCED) screening tests. The results strongly affirm that these innovative, blood-based technologies are not just a possibility for the future, but a rapidly advancing reality that healthcare leaders are eager to embrace.
The Industry is Ready: High Awareness and Support
The survey, which polled clinicians and researchers (excluding test developers), revealed significant awareness of leading MCED platforms. More importantly, it showed overwhelming support for the direction of the field:
- Over half of respondents were familiar with tests from the leading three MCED companies.
- An impressive 86% of respondents, when asked from a patient’s perspective, said they would choose to receive an MCED test if offered as part of a clinical trial or regular care. Their reasoning? A shared interest in advancing science and addressing the critical gaps in screening for currently hard-to-detect cancers.
This level of interest underscores a fundamental belief across the precision medicine community: MCED tests represent a promising advancement in early cancer detection.
A Clear Path to Validation and Standardization
While the survey showed high interest, it also highlighted the industry’s pragmatic focus on rigorous clinical utility data—a necessary step for any breakthrough medical technology.
- Over 60% of participants cited a significant stage shift (finding cancers earlier in screened populations) in randomized controlled trials as the most critical data point for regulatory approval.
- The main perceived barriers to implementation were the need for established follow-up protocols for positive test results and managing the risk of false positives. This highlights an opportunity for the field to standardize clinical care pathways around MCED results.
An Optimistic Future for Coverage and Care
Looking ahead, the community is highly optimistic about the adoption and reimbursement of MCED tests:
- Medicare Support: A resounding 78% of participants support Congress passing legislation to mandate Medicare coverage for FDA-approved MCED tests.
- Reimbursement Projected: Over half (54%) believe these tests will be reimbursed for those over 50 within the next five years.
This widespread support for future coverage signals confidence that MCED testing will transition from niche technology to standard of care, ensuring more equitable and structured access for diverse populations.
The enthusiasm captured in this survey is a powerful signal. It confirms that the scientific community and future patients are ready for the revolution in cancer screening that Multi-Cancer Early Detection offers. We at Precision Epigenomics are proud to be a part of this vital journey.
About Precision Epigenomics
Precision Epigenomics is a biotechnology company dedicated to transforming cancer diagnostics through advanced epigenetic technology. Its flagship test, EPISEEK-MCED, delivers broad, early, and extremely sensitive multi-cancer early detection using a single blood sample.
Forward-Looking Statements
Certain matters discussed in this press release may constitute forward-looking statements within the meaning of federal securities laws. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to several factors, some of which are not within the control of the company.
Media Contact
Jannalee Johnson
Precision Epigenomics Inc.
+1 520-372-7522
support@precision-epigenomics.com